Assessment of proliferating cell nuclear antigen in nasopharyngeal carcinoma tissue and its relation to clinical findings

European Journal of Cancer Part B: Oral Oncology

Volumn 33, Issue 1, 1997, Pages 13-18

  Chan, A T C ^b   Ho, S ^b   Teo, P M L ^b   Tjong, J ^b   Choi, J ^b   Lee, W Y ^b   Chang, A R ^a   Kwan, W H ^b   Leung, W T ^b   Johnson, P J ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b NONE

Author keywords

Labelling index; Nasopharyngeal carcinoma; Proliferating cell nuclear antigen

Indexed keywords

CYCLINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM PROTEINS; NEOPLASM STAGING; PROLIFERATING CELL NUCLEAR ANTIGEN; PROSPECTIVE STUDIES; REMISSION INDUCTION; TIME FACTORS;

EID: 0030937441     PISSN: 09641955     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0964-1955(96)00029-2     Document Type: Article

References (30)

1. 1. Bravo, R., Frank, R., Blundell, P. A. and Macdonald-Bravo, H., Cyclin/PCNA is the auxiliary protein of DNA polymerase-δ. Nature, 1987, 326, 515-520.
2. 2. Yu, C. C. W., Woods, A. L. and Levison, D. A., The assessment of cellular proliferation by immunohistochemistry: a review of currently available methods and their applications. Histochemistry Journal, 1992, 24, 121-131.
3. 3. McCormick, D. and Hall, P. A., The complexities of proliferating cell nuclear antigen. Histopathology, 1992, 21, 591-594.
4. 4. Mayer, A., Takimoto, M., Schellander, G., Kofler, K. and Ludwig, H., The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer, 1993, 71, 2454-2460.
5. 5. Thomas, H., Nasim, M. M., Sarraf, C. E., et al., Proliferating cell nuclear antigen (PCNA) immunostaining - a prognostic factor in ovarian cancer? British Journal of Cancer, 1995, 71, 357-362.
6. 6. Yonemura, Y., Kimura, H., Fushida, S., et al., Analysis of proliferative activity using anti-proliferating cell nuclear antigen antibody in gastric cancer tissue specimens obtained by endoscopic biopsy. Cancer, 1993, 71, 2448-2453.
7. 7. Jain, S., Filipe, M. I., Hall, P. A., Wassem, N., Lane, D. P. and Levison, D. A., Prognostic value of proliferating cell nuclear antigen in gastric carcinoma. Journal of Clinical Pathology, 1991, 44, 655-659.
8. 8. Lipponen, P. K. and Eskelinen, M. J., Cell proliferation of transitional cell bladder tumours determined by PCNA/cyclin immunostaining and its prognostic value. British Journal of Cancer, 1992, 66, 171-176.
9. 9. Ng, I. O. L., Lai, E. C. S., Ng, M., Fan, S. T., Chan, A. S. Y. and So, M. K. P., Prognostic significance of proliferating cell nuclear antigen expression in hepatocellular carcinoma. Cancer, 1994, 73, 2268-2274.
10. 10. Oka, K., Hoshi, T. and Arai, T., Prognostic significance of the PC 10 index as a prospective assay for cervical cancer treated with radiation therapy alone. Cancer, 1992, 70, 1545-1544.
11. 11. Woods, A. L., Hall, P. A., Shepherd, N. A., et al., The assessment of proliferating cell nuclear antigen (PCNA) immunostaining in primary gastrointestinal lymphomas and its relationship to histological grade, S + G2 + M phase fraction (flow cytometric analysis) and prognosis. Histopathology, 1991, 19, 21-27.
12. 12. Heegaard, S. and Broendstrup, O., Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis. Cancer, 1995, 76, 1809-1813.
13. 13. Bianchi, S., Paglierani, M., Zampi, G., et al., Prognostic value of proliferating cell nuclear antigen in lymph node-negative breast cancer patients. Cancer, 1993, 72, 120-125.
14. 14. Hall, P. A., Coates, P. J., Goodlad, R. A., Hart, I. R. and Lane, D. P., Proliferating cell nuclear antigen expression in non-cycling cells may be induced by growth factors in vivo. British Journal of Cancer, 1994, 70, 244-247.
15. 15. Shivji, M. K. K., Kenny, M. K. and Wood, R. D., Proliferating cell nuclear antigen (PCNA) is required for DNA excision repair. Cell, 1992, 69, 1-20.
16. 16. World Health Organisation Handbook for reporting results of cancer treatment. World Health Organisation, Geneva, 1979.
17. 17. Ho, J. H. C., An epidemiologic and clinical study of nasopharyngeal carcinoma. International Journal of Radiation Oncology Biology and Physics, 1978, 4, 183-198.
18. 18. Teo, P., Shiu, W., Leung, S. F. and Lee, W. Y., Prognostic factors in nasopharyngeal carcinoma investigated by computer tomography - an analysis of 659 patients. Radiother Oncol, 1992, 23, 79-93.
19. 19. Sham, J. S. T. and Choy, D., Prognostic factors of nasopharyngeal carcinoma: a review of 759 patients. British Journal of Radiology, 1989, 63, 51-58.
20. 20. Neel, H. B., Pearson, G. R. and Taylor, W. F., Antibody-dependent cellular cytotoxicity: relation to stage and disease course in North American patients with nasopharyngeal carcinoma. Archives Otolaryngology, 1984, 10, 742-747.
21. 21. Pearson, G. R., Neel, H. B., Weiland, L. H., et al., Antibody-dependent cellular cytotoxicity and disease course in North American patients with nasopharyngeal carcinoma: a prospective study. International Journal of Cancer, 1984, 33, 777-782.
22. 22. De-Vathaire, F., Sancho-Garnier, H., De-Thé, H., et al., Prognostic value of EBV markers in the clinical management of nasopharyngeal carcinoma (NPC): a multicenter follow-up study. International Journal of Cancer, 1988, 42, 176-181.
23. 23. Yip, T. T. C., Ngan, R. K. C., Lau, W. H., et al., A possible prognostic role of immunoglobulin-G antibody against recombinant Epstein-Barr virus BZLF-1 transactivator protein ZEBRA in patients with nasopharyngeal carcinoma. Cancer, 1994, 74, 2414-2424.
24. 24. Chan, A. T. C., Ho S., Teo, P. M. L., et al., In vitro uptake of bromodeoxyuridine by human nasopharyngeal carcinoma (NPC) and its relation to clinical findings. European Journal of Cancer, Oral Oncology, 1996, 32B, 50-54.
25. 25. Laboratory of Tumour Viruses of the Cancer Institute and Laboratory of Tumour Viruses of the Institute of Epidemiology, Chinese Academy of Medical Sciences. Establishment of an epithelioid cell line and fusiform line from a patient with nasopharyngeal carcinoma. Sci Sin, 1978, 21, 127-134.
26. 26. Teo, P. M. L., Tsao, S. Y., Ho, J. H. C. and Yu, P., A proposed modification of the Ho stage-classification for nasopharyngeal carcinoma. Radiother Oncol, 1991, 21, 11-23.
27. 27. Teo, P., Tsao, S. Y., Shiu, W., et al., A clinical study of 407 cases of nasopharyngeal carcinoma in Hong Kong. International Journal of Radiation Oncology Biology and Physics, 1989, 17, 515-530.
28. 28. Tubiana, M. and Courdi, A., Cell proliferation kinetics in human solid tumours: relation to probability of dissemination and long-term survival. Radiother Oncol, 1989, 15, 1-18.
29. 29. Nakae, S., Nakamura, T., Shirono, J., et al., Analysis of proliferative activity using antiproliferating cell nuclear antigen antibody in colorectal cancer. J Surg Oncol, 1995, 60, 149-153.
30. 30. Mighell, A., PCNA and p53. European Journal of Cancer, Oral Oncology, 1995, 31B, 403-404.